Remove 2019 Remove Safety Remove Side effects
article thumbnail

Is DTC effective?

World of DTC Marketing

During the first quarter of 2020, the number of telehealth visits increased by 50%, compared with the same period in 2019, with a 154% increase in visits noted in surveillance week 13 in 2020, compared with the same period in 2019. What are the side effects? That belief is out the window.

article thumbnail

Novel anti-epileptic drug demonstrates efficacy

European Pharmaceutical Review

A new approach to potassium-channel openers for epilepsy Critically, XEN1101 combines the effectiveness of potassium-channel openers with the safety of more traditional drugs, stated study lead author and neurologist Dr Jacqueline French. It ran between January 2019 and September 2021.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Almirall/Lilly lebrikizumab offers potential long-term management of atopic dermatitis

pharmaphorum

The week 16 data of lebrikizumab […] points towards a drug with robust efficacy with hardly any safety trade-offs. Minor side effects to long-term maintenance balance. Any clinical study seeks to achieve maximum results efficacy with minimal occurrence of side effects. However, side effects do happen.

article thumbnail

Newron says pivotal treatment-resistant schizophrenia trial is a go

pharmaphorum

Side-effect data from the open-label studies was also encouraging, helping to downplay concerns abut evenamide’s cardiovascular and central nervous system safety that emerged in 2019.

article thumbnail

Developing the EU’s first intestinal microbiota-based biologic

European Pharmaceutical Review

The main objective was to evaluate the efficacy and safety of MBK-01 compared to fidaxomicin, providing significant insights into the potential of MBK-01 as a treatment for primary or recurrent CDI and contributing to the advancement of microbiome-based therapies. 2019; 13(1):16-24. Adverse events were relatively low in both groups (2.22

Safety 111
article thumbnail

Galapagos’ new CEO Paul Stoffels wields axe in bid to go ‘forward, faster’

pharmaphorum

Galapagos is in the roll-out phase for its first commercial products – JAK1 inhibitor Jyseleca (filgotinib) for rheumatoid arthritis – which has been approved in Europe and Japan but fell foul of FDA concerns about the class’s safety and was rejected in the US. Jyseleca has made €60.5

article thumbnail

Digital Self-Neuromodulation Therapy for PTSD: Interview with Oded Kraft, CEO of GrayMatters Health

Medgadget

These treatments at times come with a long list of side effects, leaving many patients in search of an effective long-term solution. For some patients with PTSD, psychotherapy may not be an effective option, they may find talking about their traumatic experience stress inducing, untherapeutic or ineffective.